CVRx® Receives MR-Conditional Labeling Approval for its Barostim™ Heart Failure System
09 mai 2022 08h30 HE
|
CVRx, Inc.
Heart failure patients implanted with Barostim can now receive conditional MRI scans MINNEAPOLIS, May 09, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), developer of the world’s...
New Data Validates Blood Volume Analysis Guided-Care, Improves Survival in Patients with Advanced Heart Failure Supported with Left Ventricular Assist Device
02 mai 2022 08h00 HE
|
Daxor Corporation
Study Presented at the International Society for Heart and Lung Transplant 42nd Annual Meeting and Scientific Sessions 2022 Oak Ridge, TN, May 02, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation...
New Study from Duke Heart Demonstrates the Unique Accuracy and Utility of Daxor’s Blood Volume Diagnostic (BVA-100®) for Improving Worsening Heart Failure
06 avr. 2022 08h00 HE
|
Daxor Corporation
Study Presented at the 71st Annual American College of Cardiology Meeting Oak Ridge, TN, April 06, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume...
Cytokinetics Announces Results From METEORIC-HF and Additional Data From GALACTIC-HF Presented at the American College of Cardiology 71st Annual Scientific Session
03 avr. 2022 09h45 HE
|
Cytokinetics, Incorporated
No Effect of Omecamtiv Mecarbil On Exercise Capacity in Patients with Heart Failure with Reduced Ejection Fraction in METEORIC-HF Healthcare Resource Utilization and Cost Analysis from...
Daxor Corporation to Participate in the Maxim Group 2022 Virtual Growth Conference
23 mars 2022 08h00 HE
|
Daxor Corporation
Oak Ridge, TN, March 23, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces that President and CEO Michael Feldschuh will...
Imara to Webcast Conference Call of Full Year 2021 Financial Results and Business Highlights
08 mars 2022 07h00 HE
|
Imara, Inc.
BOSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Global Cardiac Resynchronization Therapy Markets Analysis & Forecasts Report 2017-2021 & 2022-2030 Featuring Abbott, Boston Scientific, Medtronic, Biotronik Se & Co, & Microport Scientific
04 mars 2022 04h48 HE
|
Research and Markets
Dublin, March 04, 2022 (GLOBE NEWSWIRE) -- The "Cardiac Resynchronization Therapy Market Size, Share & Trends Analysis Report by Product (CRT-defibrillator, CRT-pacemaker), by End User...
CVRx Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
15 févr. 2022 16h05 HE
|
CVRx, Inc.
MINNEAPOLIS, Feb. 15, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative...
CVRx to Report Fourth Quarter and Fiscal Year 2021 Financial Results on February 15, 2022
01 févr. 2022 16h05 HE
|
CVRx, Inc.
MINNEAPOLIS, Feb. 01, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation...
Imara Announces FDA Clearance of Investigational New Drug Application (IND) for Tovinontrine (IMR-687) for Heart Failure with Preserved Ejection Fraction (HFpEF)
25 janv. 2022 07h00 HE
|
Imara, Inc.
Expanding patient base and potential of Imara’s small molecule oral inhibitor of phosphodiesterase-9 (PDE9) alongside hemoglobin disorders Phase 2 trial aims to select HFpEF patients with enriched...